{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-22-005640","form_type":"8-K","ticker":"UG","cik":"0000101295","company_name":"UNITED GUARDIAN INC","filed_at":"2022-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:54.587488+00:00","generated_at":"2026-06-24T00:12:00.200251+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"United-Guardian Q2 net income down 53% to $0.14/share; H1 sales up 6%","bullets":["H1 2022 sales $7.52M (+6% YoY); net income $1.54M ($0.34/share) vs $2.53M ($0.55/share) in H1 2021.","Q2 net income fell to $633K ($0.14/share) from $1.34M ($0.29/share); sales down slightly to $3.63M.","Profit hit by higher raw material and shipping costs and decline in marketable securities value.","Pharmaceutical product sales up 8% QoQ; non-pharmaceutical medical product sales surged 55% on China order.","Company implemented price increases in April to partially offset rising costs; optimistic on securities recovery."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-22-005640","json":"https://secwatch.observer/filing/0001171843-22-005640.json","markdown":"https://secwatch.observer/filing/0001171843-22-005640.md","text":"https://secwatch.observer/filing/0001171843-22-005640.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/101295/000117184322005640/0001171843-22-005640-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/101295/000117184322005640/f8k_080122.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:12:00.200251+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}